Menu Search
Equities

Penumbra Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0P8:BRN

Penumbra Inc

Actions
  • Price (CHF)239.06
  • Today's Change0.00 / 0.00%
  • Shares traded10.00
  • 1 Year change--
  • Beta0.8133
Data delayed at least 15 minutes, as of Sep 15 2023.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.

  • Revenue in USD (TTM)1.33bn
  • Net income in USD164.03m
  • Incorporated2004
  • Employees4.50k
  • Location
    Penumbra IncOne Penumbra PlaceALAMEDA 94502United StatesUSA
  • Phone+1 (302) 531-0855
  • Fax+1 (302) 531-3150
  • Websitehttps://www.penumbrainc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.